Award Also Known as the Oscar of the Biotechnology Industry
ROCKVILLE, Md.–(BUSINESS WIRE)–20/20 GeneSystems, Inc. is proud to announce that in partnership with Linkou Chang Gung Memorial Hospital, the largest hospital in Taiwan, it has won the 2020 Taipei Biotech “Technology Transfer Cooperation Award” Gold Medal Award, the Oscar in the biotechnology industry, for its OneTest an artificial intelligence (AI) powered blood test that can assist in the early detection of many common cancers.
Linkou Chang Gung Memorial Hospital, a multi-specialty hospital recognized as a powerhouse and pioneer in innovation, research and teaching, used its technology transfer rights to exclusively authorize 20/20 GeneSystems “Multiple Cancer Screening with Tumor Markers and Machine Learning Algorithms” technology platform to qualify.
The technology has been patented in Taiwan and the United States. Through the combination of tumor markers, machine learning and physician interpretation, OneTest can screen for multiple cancers at one time. The screening process provides no radiation exposure but rather low invasive detection, reducing the psychological pressure of the tested patients, and making the interpretation of test results more objective through blood sampling data and AI-assisted analysis.
“We are so proud to partner with Linkou Chang Gung Memorial Hospital and win the Gold Medal Taipei Biotech Award. The OneTest is based on innovative technology that drives cancer screening with AI technology, which is helpful for early cancer screening and early intervention treatment to improve patient survival rate,” said founder of 20/20 GeneSystems, Jonathan Cohen. “The award properly reflects the great value OneTest brings to the hundreds of millions of people who routinely receive tumor markers screenings as part of their annual physical exam packages in eastern Asia, especially in China.”
“This adds to the list of major achievements we have made in part 6 months, including the publication of a peer-reviewed research article in a prestigious scientific journal, and the admission to and graduation from the highly selective Ping An Accelerator,” said Dr. Jiming Zhou, the head of 20/20’s eastern Asia operations.
20/20 GeneSystems has its roots in machine learning as a result of the work it has done over the years to develop OneTest. In the U.S., OneTest has been used by firefighters and departments across the U.S. to help combat firefighting related cancers.
Since late March, 20/20 has been importing and distributing in the U.S. rapid COVID-19 antibody tests and will continue to work with the manufacturers of those tests to help them obtain EUAs for their use at the point of care in accordance with the latest Guidance from the FDA.
About 20/20 GeneSystems:
20/20 GeneSystems, Inc. is a Rockville, MD based company focused on innovative diagnostics and detection products. In addition to the company’s blood tests for early cancer detection 20/20 has also commercialized its patented BioCheck® detection kit to help fire departments and other emergency response organizations screen suspicious powders.
The information set forth in this document includes statements, estimates and projections with respect to our anticipated future performance and other forward-looking statements, which are subject to risks, uncertainties and assumptions. In some cases, you can identify these statements by forward-looking words such as “may”, “might”, “will”, “should”, “expect”, “plan”, “anticipate”, “believe”, “estimate”, “predict”, “potential”, “future” or “continue”, the negative of these terms and other comparable terminology. Such forward-looking statements are based on current plans, estimates and expectations and are made pursuant to the Private Securities Litigation Reform Act of 1995. These statements, estimates and projections are based upon various assumptions that we made concerning our anticipated results and industry trends, which may or may not occur. We are not making any representations as to the accuracy of these statements, estimates or projections. Our actual performance may be materially different from the statements, estimates or projections set forth below based upon a number of factors, including those contained in the Risk Factor section of the filings that we make with the U.S. Securities and Exchange Commission. We are under no duty to update any of these forward-looking statements to conform them to actual results or revised expectation.
About the Taipei Biotech Awards
The Taipei Biotech Awards also known as the “Biotech Oscar” provides an excellent platform for Taiwan’s best biotech firms to be recognized in the international arena. In 2004, the Taipei City Government first launched the “Taipei Biotech Awards.” The award is designed to recognize and award innovation, exploration, development, technology transfer, and product marketing. Experts in biotech, finance, and financial-intelligence are invited to be a part of the award investigation committee. Over the years, the Taipei Biotech Awards has gained prestige in the biotech industry, government and academia industries as a result of a rigorous, impartial and professional review process. Most of the award-winning companies are under rapid growth, and nearly 60% of them have successfully gone to market. Their products or technologies have won high regards at international biotech conferences and earned a total of 430 million TWD (Taiwan New Dollar) through technology licensing.
RMR & Associates